Clinical Trials Logo

Neoplasms, Prostate clinical trials

View clinical trials related to Neoplasms, Prostate.

Filter by:

NCT ID: NCT00148928 Completed - Neoplasms, Prostate Clinical Trials

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

Start date: March 1, 2005
Phase: Phase 1
Study type: Interventional

Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, will be treated with the P501-AS15 vaccine as out-patients. The maximum dose will be 16 vaccinations, given over a period of approximately one year. Thereafter, the patients' long-term safety and PSA status will be followed over a period of approximately 11 months.

NCT ID: NCT00056407 Completed - Neoplasms, Prostate Clinical Trials

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

REDUCE
Start date: March 2003
Phase: Phase 3
Study type: Interventional

This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.